Gäckler Anja, Mülling Nils, Völk Kim, Wilde Benjamin, Eisenberger Ute, Rohn Hana, Horn Peter A, Witzke Oliver, Lindemann Monika
Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Vaccines (Basel). 2021 Dec 6;9(12):1438. doi: 10.3390/vaccines9121438.
In organ transplant recipients, the rate of invasive pneumococcal diseases is 25 times greater than in the general population. Vaccination against is recommended in this cohort because it reduces the incidence of this severe form of pneumococcal infection. Previous studies indicate that transplant recipients can produce specific antibodies after pneumococcal vaccination. However, it remains unclear if vaccination also induces specific cellular immunity. In the current study on 38 kidney transplant recipients, we established an interferon-γ ELISpot assay that can detect serotype-specific cellular responses against . The results indicate that sequential vaccination with the conjugated vaccine Prevenar 13 and the polysaccharide vaccine Pneumovax 23 led to an increase of serotype-specific cellular immunity. We observed the strongest responses against the serotypes 9N and 14, which are both components of Pneumovax 23. Cellular responses against correlated positively with specific IgG antibodies ( = 0.32, = 0.12). In conclusion, this is the first report indicating that kidney transplant recipients can mount specific cellular responses after pneumococcal vaccination. The ELISpot we established will allow for further investigations. These could help to define, for example, factors influencing specific cellular immunity in immunocompromised cohorts or the duration of cellular immunity after vaccination.
在器官移植受者中，侵袭性肺炎球菌疾病的发生率比普通人群高25倍。建议对该队列进行疫苗接种，因为它可降低这种严重形式的肺炎球菌感染的发生率。先前的研究表明，移植受者在接种肺炎球菌疫苗后可产生特异性抗体。然而，疫苗接种是否也能诱导特异性细胞免疫仍不清楚。在当前这项针对38名肾移植受者的研究中，我们建立了一种干扰素-γ ELISpot检测方法，该方法可检测针对肺炎球菌的血清型特异性细胞反应。结果表明，先后接种结合疫苗沛儿13（Prevenar 13）和多糖疫苗肺炎球菌多糖疫苗23价（Pneumovax 23）可导致血清型特异性细胞免疫增强。我们观察到针对9N和14血清型的反应最强，这两种血清型均为肺炎球菌多糖疫苗23价的成分。针对肺炎球菌的细胞反应与特异性IgG抗体呈正相关（r = 0.32，P = 0.12）。总之，这是第一份表明肾移植受者在接种肺炎球菌疫苗后可产生特异性细胞反应的报告。我们建立的ELISpot检测方法将有助于进一步研究。例如，这些研究可能有助于确定影响免疫受损人群中特异性细胞免疫的因素或接种疫苗后细胞免疫的持续时间。
